Literature DB >> 2105828

Assessment of renal and skeletal components of hypercalcemia.

D J Hosking1.   

Abstract

The management of hypercalcemia of malignancy is guided by assessments of its various components. Since the intestine usually makes no contribution to hypercalcemia under these circumstances, the problem is to measure the net efflux of calcium out of bone and the ability of the kidneys to excrete the unwanted calcium load. Established relationships between serum and urinary calcium excretion rates allow the quantitation of the relative contribution of an impaired glomerular filtration rate, of reduced renal tubular calcium reabsorption, and of increased bone resorption. Since the renal handling of calcium is closely related to that of sodium in the proximal nephron, the rate of sodium excretion is an important variable in these measurements. A practical approach to the separation of hypercalcemia into its renal and skeletal components is described in this article. Examples of how these measurements can be used to assess the responses to various types of therapy for malignancy-associated hypercalcemia are also given.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105828     DOI: 10.1007/bf02553288

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  17 in total

1.  Cellular actions of vasopressin in the mammalian kidney.

Authors:  T P Dousa; H Valtin
Journal:  Kidney Int       Date:  1976-07       Impact factor: 10.612

2.  Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

Authors:  S R Heller; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

3.  Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy.

Authors:  D J Hosking; M D Stone; J W Foote
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Renal tubular transport of calcium: update.

Authors:  Z S Agus
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

5.  Relation between serum and urinary calcium with particular reference to parathyroid activity.

Authors:  M Peacock; W G Robertson; B E Nordin
Journal:  Lancet       Date:  1969-02-22       Impact factor: 79.321

6.  Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma.

Authors:  N A Breslau; J L McGuire; J E Zerwekh; E P Frenkel; C Y Pak
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

7.  Rehydration in the treatment of severe hypercalcaemia.

Authors:  D J Hosking; A Cowley; C A Bucknall
Journal:  Q J Med       Date:  1981

8.  Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.

Authors:  M L Binstock; G R Mundy
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

Review 9.  Calcium transport in the nephron.

Authors:  W N Suki
Journal:  Am J Physiol       Date:  1979-07

10.  Parathyroid hormone-like changes in renal calcium and phosphate reabsorption induced by Leydig cell tumor in thyroparathyroidectomized rats.

Authors:  R Rizzoli; J Caverzasio; H Fleisch; J P Bonjour
Journal:  Endocrinology       Date:  1986-09       Impact factor: 4.736

View more
  3 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia.

Authors:  C Camus; C Charasse; I Jouannic-Montier; P Seguin; Y L Tulzo; J Bouget; R Thomas
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.